LONDON, ONTARIO--(Marketwire - March 18, 2008) - Stellar Pharmaceuticals Inc. (“Stellar”) (TSX VENTURE: SLX)(OTCBB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today reported receiving its first NeoVisc order from Torrex Chiesi Pharma GmbH (“Torrex Chiesi”), based in Vienna, Austria. NeoVisc is Stellar’s proprietary, high molecular weight hyaluronate viscosupplement used for the treatment of osteoarthritis. Stellar entered into a distribution agreement with Torrex Chiesi in November 2007.
